Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie

At Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie, clinical trials in cardiovascular diseases focus on conditions such as acute coronary syndrome, atrial fibrillation, heart failure, and ischemic stroke. These studies are designed to test new ways to prevent major heart and blood vessel events, improve clot prevention, and evaluate safer treatment options for patients who need urgent procedures or cannot use standard anticoagulation.

• Acute coronary syndrome and recurrent cardiovascular event prevention
• Atrial fibrillation and stroke risk reduction
• Heart failure, including preserved and reduced ejection fraction forms
• Ischemic stroke, thromboembolism, and bleeding management

The site’s work in this area emphasizes better protection against thrombosis while balancing bleeding risk, with several trials also exploring improved diagnostic tools for coronary artery disease.

A major part of the research portfolio centers on neoplasms and hemic and lymphatic diseases, especially non-small cell lung cancer, small cell lung cancer, multiple myeloma, lymphoma, and chronic lymphocytic leukemia. These trials are mainly evaluating new cancer therapies and combination approaches to improve tumor control, extend survival, and help patients whose disease has returned or no longer responds well to standard treatment.

• Non-small cell lung cancer and other advanced solid tumors
• Small cell lung cancer and neuroendocrine cancers
• Multiple myeloma, myelofibrosis, and lymphoma
• Chronic lymphocytic leukemia and related B-cell malignancies

The research at this hospital frequently compares emerging immunotherapies and targeted treatments with established care, reflecting a strong focus on advancing options for difficult-to-treat blood cancers and lung tumors.

The clinical department of artificial kidney supports trials in nutritional and metabolic diseases and kidney disease, including chronic kidney disease, immunoglobulin A nephropathy, and complications seen in people receiving hemodialysis. These studies aim to slow kidney decline, reduce protein loss in the urine, improve mineral balance, and strengthen long-term care for patients with advanced kidney disease.

• Chronic kidney disease with proteinuria or hypertension
• Immunoglobulin A nephropathy and kidney function preservation
• Secondary hyperparathyroidism in dialysis patients
• End-stage kidney disease and supportive metabolic care

This research area highlights practical questions in everyday nephrology, including how to protect kidney function and improve outcomes for people living with advanced renal disease.

Another strong theme is immune system diseases and related inflammatory conditions such as Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, Sjögren’s syndrome, psoriatic arthritis, and myasthenia gravis. Trials in this group are generally aimed at reducing inflammation, improving symptom control, and testing whether newer immune-targeted therapies can provide more durable relief.

• Crohn’s disease and ulcerative colitis
• Systemic lupus erythematosus and Sjögren’s syndrome
• Myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy
• Psoriatic arthritis and other immune-mediated disorders

The site contributes to research that seeks more precise immunomodulatory treatment strategies, with an emphasis on both effectiveness and longer-term safety.

Trials in respiratory tract diseases and allergic conditions include pulmonary arterial hypertension, allergic rhinitis, and chronic rhinosinusitis. The goal of this work is to evaluate treatments that may improve breathing, reduce allergy-related symptoms, and better manage chronic airway inflammation in both children and adults.

• Pulmonary arterial hypertension
• Seasonal allergic rhinitis and house dust mite allergy
• Chronic rhinosinusitis without nasal polyps
• Asthma-related allergic disease

This area shows a balance between symptom relief research and studies designed to understand how long-term disease control can be improved.

The site also participates in research on nervous system diseases, including multiple sclerosis, Alzheimer’s disease, mild cognitive impairment, and chronic inflammatory demyelinating polyradiculoneuropathy. These trials are focused on slowing disease progression, preserving function, and assessing whether new therapies can improve cognition or reduce neurologic disability.

• Multiple sclerosis and long-term disease control
• Alzheimer’s disease and cognitive decline
• Mild cognitive impairment linked to dementia
• Peripheral nerve and immune-related neurologic disorders

Research in this field reflects a broader effort to find treatments that protect brain and nerve function while remaining safe for prolonged use.

Additional trials cover nutritional and metabolic diseases, hormonal diseases, and musculoskeletal diseases, including type 2 diabetes, obesity-related heart failure, myelofibrosis, and axial spondyloarthritis. The purpose of these studies is to test new treatment approaches that may improve metabolic control, reduce disease burden, and support better daily functioning.

• Type 2 diabetes mellitus
• Metabolic and weight-related cardiovascular complications
• Myelofibrosis with blood count and symptom concerns
• Axial spondyloarthritis and other inflammatory musculoskeletal disorders

Across these studies, the site contributes to research aimed at improving both disease control and everyday quality of life.